Clinical Trial Finder

Inclusion Criteria:

• - Participants consented to the PsA inception cohort (MONITOR-PsA) and to be approached for alternate interventional therapies.

• - Participants with mild disease as defined by: - Oligoarticular disease with <5 active joints at baseline assessment.

• - Low disease activity as defined by a PsA disease activity score (PASDAS) ≤3.2.

• - Low impact of disease as defined a PsA impact of disease (PSAID) ≤4.

• - Participant is willing and able to give informed consent for participation in the trial.

• - Male or female.

• - Aged 18 years or above.

• - Female Participants of child bearing potential and male Participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception (defined as true abstinence, oral contraceptives, implants, intrauterine device, barrier method with spermicide, or surgical sterilization) during the trial and for 3 months thereafter if receiving DMARD therapy (excluding sulfasalazine).

• - Participant has clinically acceptable laboratory results within 6 weeks of enrolment: - Haemoglobin count > 8.5 g/dL.

• - White blood count (WBC) > 3.5 x 109/L.

• - Absolute neutrophil count (ANC) > 1.5 x 109/L.

• - Platelet count > 100 x 109/L.

• - ALT and alkaline phosphatase levels <3 x upper limit of normal.

• - In the Investigator's opinion, is able and willing to comply with all trial requirements.

• - Willing to allow his or her GP and consultant, if appropriate, to be notified of participation in the trial.

Exclusion Criteria:

• - ≥1 poor prognostic factors for psoriatic arthritis, from.

• - raised C reactive protein (CRP) defined as > 4g/dl for standard non-hsCRP.

• - radiographic damage defined as the presence of ≥ 1 erosion on plain radiographs of the hands and feet.

• - health assessment questionnaire (HAQ) score > 1.

• - Contraindications to non-steroidal anti-inflammatory drugs.

• - Previous treatment for articular disease with synthetic DMARDs (including methotrexate, leflunomide or sulfasalazine) or biologic DMARDs (including TNF, IL12/23 or IL17 inhibitor therapies) or targeted synthetic DMARDs (PDE4 of JAK inhibitor therapies).

• - Female patient who is pregnant, breast feeding or planning pregnancy during the course of the trial.

• - Significant renal or hepatic impairment.

• - Scheduled elective surgery or other procedures requiring general anaesthesia during the trial.

• - Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patients at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.

• - Patients who have participated in another research trial involving an investigational product in the past 12 weeks.

Arm 1: Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard practice in these PsA clinics following current international recommendations and National requirements for the prescription of biologic therapy. Whilst physician discretion is used, most commonly Initial therapy will be with methotrexate alone (15mg/week rising to 25mg/week as tolerated by week 8 of therapy) unless this is contraindicated. In cases of non-response or intolerance to methotrexate, participants will have an alternative DMARD (most commonly sulfasalazine or leflunomide) added or switched to at the discretion of the rheumatologist. In cases of failure of two DMARDs, treatment can be escalated to biologic therapy as per National Institute for Health and Clinical Excellence (NICE) recommendations usually with a TNF inhibitor as first line. If the requisite disease activity is not met or if there are contraindications to biologics, alternative DMARD combinations will be used. Further details are available in the PsA clinic treatment protocol which is Appendix D in the MONITOR-PsA protocol. Arm 2: Symptomatic therapy arm. The intervention will delay standard treatment with disease-modifying anti-rheumatic drugs (DMARDs) and use local glucocorticoid injections to affected joints instead. Oral non-steroidal anti-inflammatory drugs (NSAIDs) will also be allowed as concomitant medication as indicated for individuals. Local glucocorticoid injections will include injections with methylprednisolone or triamcinolone. All active joints will be treated with glucocorticoid injections. Glucocorticoid injections can be either be given as an intra-articular injection to an inflamed joint or as an intra-muscular injection if multiple joints are involved. If any joint requires more than 2 local injections of glucocorticoid within a 6 month period, then the patient is deemed to have failed symptomatic therapy and will be withdrawn from the treatment protocol and be treated as per usual care (in most cases with DMARD therapy). If Participants require DMARD therapy, they will be offered rescue therapy as per usual clinical care but will be asked to continue with data collection for the trial. This is to ensure that sufficient data is collected for the trial but risks in delaying treatment to the individual are mitigated.

Arms

Interventions